Parenterally Administered Norovirus GII.4 Virus-Like Particle Vaccine Formulated with Aluminum Hydroxide or Monophosphoryl Lipid A Adjuvants Induces Systemic but Not Mucosal Immune Responses in Mice

Overview

Journal J Immunol Res

Publisher Wiley

Specialty Allergy & Immunology

Date 2018 Apr 24

PMID 29682589

Citations 7

Authors

Suvi Heinimaki

Maria Malm

Timo Vesikari

Vesna Blazevic

Affiliations

Soon will be listed here.

Abstract

Norovirus (NoV) is a main cause of acute gastroenteritis across all ages worldwide. NoV vaccine candidates currently in clinical trials are based on noninfectious highly immunogenic virus-like particles (VLPs) delivered intramuscularly (IM). Since NoV is an enteric pathogen, it is likely that mucosal immunity has a significant role in protection from infection in the intestine. Due to the fact that IM delivery of NoV VLPs does not generate mucosal immunity, we investigated whether NoV genotype GII.4 VLPs coadministered with aluminum hydroxide (Al(OH)) or monophosphoryl lipid A (MPLA) would induce mucosal antibodies in mice. Systemic as well as mucosal IgG and IgA antibodies in serum and intestinal and nasal secretions were measured. As expected, strong serum IgG, IgG1, and IgG2a antibodies as well as a dose sparing effect were induced by both Al(OH) and MPLA, but no mucosal IgA antibodies were detected. In contrast, IN immunization with GII.4 VLPs without an adjuvant induced systemic as well as mucosal IgA antibody response. These results indicate that mucosal delivery of NoV VLPs is needed for induction of mucosal responses.

Citing Articles

Noroviruses: Evolutionary Dynamics, Epidemiology, Pathogenesis, and Vaccine Advances-A Comprehensive Review.

Omatola C, Mshelbwala P, Okolo M, Onoja A, Abraham J, Adaji D Vaccines (Basel). 2024; 12(6).

PMID: 38932319 PMC: 11209302. DOI: 10.3390/vaccines12060590.

Norovirus-Associated Gastroenteritis Vesikari Score and Pre-Existing Salivary IgA in Young Children from Rural South Africa.

Kabue J, Khumela R, Meader E, Moraes M, Traore A, Potgieter N Viruses. 2023; 15(11).

PMID: 38005863 PMC: 10674611. DOI: 10.3390/v15112185.

Norovirus Protease Structure and Antivirals Development.

Zhao B, Hu L, Song Y, Patil K, Ramani S, Atmar R Viruses. 2021; 13(10).

PMID: 34696498 PMC: 8537771. DOI: 10.3390/v13102069.

Norovirus Outbreak Surveillance, China, 2016-2018.

Jin M, Wu S, Kong X, Xie H, Fu J, He Y Emerg Infect Dis. 2020; 26(3):437-445.

PMID: 32091361 PMC: 7045832. DOI: 10.3201/eid2603.191183.

Rotavirus VP6 as an Adjuvant for Bivalent Norovirus Vaccine Produced in .

Malm M, Diessner A, Tamminen K, Liebscher M, Vesikari T, Blazevic V Pharmaceutics. 2019; 11(5).

PMID: 31083495 PMC: 6572255. DOI: 10.3390/pharmaceutics11050229.

References

Vernacchio L, Bernstein H, Pelton S, Allen C, MacDonald K, Dunn J . Effect of monophosphoryl lipid A (MPL) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers. Vaccine. 2002; 20(31-32):3658-67. DOI: 10.1016/s0264-410x(02)00413-9. View

Norton E, Bauer D, Weldon W, Oberste M, Lawson L, Clements J . The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model. Vaccine. 2015; 33(16):1909-15. DOI: 10.1016/j.vaccine.2015.02.069. View

Han M, Cheetham S, Azevedo M, Thomas C, Saif L . Immune responses to bovine norovirus-like particles with various adjuvants and analysis of protection in gnotobiotic calves. Vaccine. 2005; 24(3):317-26. DOI: 10.1016/j.vaccine.2005.07.071. View

Casella C, Mitchell T . Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci. 2008; 65(20):3231-40. PMC: 2647720. DOI: 10.1007/s00018-008-8228-6. View

Lycke N . T cell and cytokine regulation of the IgA response. Chem Immunol. 1998; 71:209-34. DOI: 10.1159/000058712. View

Tamminen K, Huhti L, Koho T, Lappalainen S, Hytonen V, Vesikari T . A comparison of immunogenicity of norovirus GII-4 virus-like particles and P-particles. Immunology. 2011; 135(1):89-99. PMC: 3246655. DOI: 10.1111/j.1365-2567.2011.03516.x. View

Huhti L, Blazevic V, Nurminen K, Koho T, Hytonen V, Vesikari T . A comparison of methods for purification and concentration of norovirus GII-4 capsid virus-like particles. Arch Virol. 2010; 155(11):1855-8. PMC: 2970802. DOI: 10.1007/s00705-010-0768-z. View

Ogra P, Karzon D, Righthand F, Macgillivray M . Immunoglobulin response in serum and secretions after immunization with live and inactivated poliovaccine and natural infection. N Engl J Med. 2010; 279(17):893-900. DOI: 10.1056/NEJM196810242791701. View

Blazevic V, Lappalainen S, Nurminen K, Huhti L, Vesikari T . Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis. Vaccine. 2011; 29(45):8126-33. DOI: 10.1016/j.vaccine.2011.08.026. View

10.

Lycke N . Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol. 2012; 12(8):592-605. DOI: 10.1038/nri3251. View

11.

Clements J, Freytag L . Parenteral Vaccination Can Be an Effective Means of Inducing Protective Mucosal Responses. Clin Vaccine Immunol. 2016; 23(6):438-441. PMC: 4895008. DOI: 10.1128/CVI.00214-16. View

12.

Sasaki S, Sumino K, Hamajima K, Fukushima J, Ishii N, Kawamoto S . Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes. J Virol. 1998; 72(6):4931-9. PMC: 110054. DOI: 10.1128/JVI.72.6.4931-4939.1998. View

13.

Kozlowski P, Williams S, Lynch R, Flanigan T, Patterson R, Cu-Uvin S . Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J Immunol. 2002; 169(1):566-74. DOI: 10.4049/jimmunol.169.1.566. View

14.

Bessa J, Schmitz N, Hinton H, Schwarz K, Jegerlehner A, Bachmann M . Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur J Immunol. 2007; 38(1):114-26. DOI: 10.1002/eji.200636959. View

15.

Herremans T, Reimerink J, Buisman A, Kimman T, Koopmans M . Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J Immunol. 1999; 162(8):5011-8. View

16.

Ramani S, Neill F, Ferreira J, Treanor J, Frey S, Topham D . B-Cell Responses to Intramuscular Administration of a Bivalent Virus-Like Particle Human Norovirus Vaccine. Clin Vaccine Immunol. 2017; 24(5). PMC: 5424242. DOI: 10.1128/CVI.00571-16. View

17.

Apostolico J, Lunardelli V, Coirada F, Boscardin S, Santoro Rosa D . Adjuvants: Classification, Modus Operandi, and Licensing. J Immunol Res. 2016; 2016:1459394. PMC: 4870346. DOI: 10.1155/2016/1459394. View

18.

Patel M, Widdowson M, Glass R, Akazawa K, Vinje J, Parashar U . Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg Infect Dis. 2008; 14(8):1224-31. PMC: 2600393. DOI: 10.3201/eid1408.071114. View

19.

Tamminen K, Lappalainen S, Huhti L, Vesikari T, Blazevic V . Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice. PLoS One. 2013; 8(7):e70409. PMC: 3724941. DOI: 10.1371/journal.pone.0070409. View

20.

Lindesmith L, Moe C, Marionneau S, Ruvoen N, Jiang X, Lindblad L . Human susceptibility and resistance to Norwalk virus infection. Nat Med. 2003; 9(5):548-53. DOI: 10.1038/nm860. View